{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:50:13Z","timestamp":1772189413372,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GGP13145"],"award-info":[{"award-number":["GGP13145"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HD084209"],"award-info":[{"award-number":["HD084209"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejmech.2020.112395","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T21:20:44Z","timestamp":1588540844000},"page":"112395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Privileged scaffold-based design to identify a novel drug-like 5-HT7 receptor-preferring agonist to target Fragile X syndrome"],"prefix":"10.1016","volume":"199","author":[{"given":"Enza","family":"Lacivita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Niso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madia Letizia","family":"Stama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Arzuaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Desaphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Ragozzino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Ciranna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Leopoldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112395_bib1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2010.08.013","article-title":"Serotonin 5-HT7 receptor agents: structure-activity relationships and potential therapeutic applications in central nervous system disorders","volume":"129","author":"Leopoldo","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2020.112395_bib2","doi-asserted-by":"crossref","first-page":"8475","DOI":"10.1021\/acs.jmedchem.7b01898","article-title":"Structure-activity relationships and therapeutic potentials of 5-HT7 receptor ligands: an update","volume":"61","author":"Modica","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-009-1626-0","article-title":"The 5-HT7 receptor and disorders of the nervous system: an overview","volume":"206","author":"Hedlund","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2020.112395_bib4","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1523\/JNEUROSCI.1790-05.2005","article-title":"5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology","volume":"25","author":"Kvachnina","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112395_bib5","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1523\/JNEUROSCI.2765-11.2012","article-title":"5-HT7R\/G12 signaling regulates neuronal morphology and function in an age-dependent manner","volume":"32","author":"Kobe","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2020.112395_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/jnc.13962","article-title":"Serotonin 5-HT7 receptor increases the density of dendritic spines and facilitates synaptogenesis in forebrain neurons","volume":"141","author":"Speranza","year":"2017","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2020.112395_bib7","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1007\/s12035-019-01690-x","article-title":"The microRNA-29a modulates serotonin 5-HT7 receptor expression and its effects on hippocampal neuronal morphology","volume":"56","author":"Volpicelli","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2020.112395_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neuropharm.2012.10.026","article-title":"The serotonin receptor 7 promotes neurite outgrowth via ERK and Cdk5 signaling pathways","volume":"67","author":"Speranza","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112395_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fnbeh.2015.00062","article-title":"Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics","volume":"9","author":"Speranza","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112395_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fncel.2014.00314","article-title":"Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegeneration","volume":"8","author":"Stankiewicz","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112395_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1515\/revneuro-2014-0009","article-title":"Selective agonists for serotonin 7 (5-HT7) receptor and their applications in preclinical models: an overview","volume":"25","author":"Di Pilato","year":"2014","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112395_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.biopsych.2012.06.008","article-title":"Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome","volume":"72","author":"Costa","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.112395_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fnbeh.2015.00065","article-title":"Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome","volume":"9","author":"Costa","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112395_bib14","doi-asserted-by":"crossref","first-page":"27746","DOI":"10.1073\/pnas.122205699","article-title":"Altered synaptic plasticity in a mouse model of fragile X mental retardation","volume":"99","author":"Huber","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.ejmech.2020.112395_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fnmol.2018.00353","article-title":"Activation of serotonin 5-HT7 receptors modulates hippocampal synaptic plasticity by stimulation of adenylate cyclases and rescues learning and behavior in a mouse model of Fragile X syndrome","volume":"11","author":"Costa","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112395_bib16","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/npp.2014.105","article-title":"Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for Rett syndrome","volume":"39","author":"De Filippis","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2020.112395_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fnbeh.2015.00086","article-title":"Long-lasting beneficial effects of central serotonin receptor 7 stimulation in female mice modeling Rett syndrome","volume":"9","author":"De Filippis","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112395_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuropharm.2017.04.024","article-title":"Stimulation of the brain serotonin receptor 7 rescues mitochondrial dysfunction in female mice from two models of Rett syndrome","volume":"121","author":"Valenti","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112395_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neuropharm.2018.10.018","article-title":"Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder","volume":"144","author":"Vigli","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112395_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fncel.2014.00250","article-title":"5-HT7 receptors as modulators of neuronal excitability, synaptic transmission and plasticity: physiological role and possible implications in autism spectrum disorders","volume":"8","author":"Ciranna","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112395_bib21","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1021\/acs.jmedchem.7b00965","article-title":"Targets for drug therapy for autism spectrum disorder: challenges and future directions","volume":"60","author":"Lacivita","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejmech.2019.03.017","article-title":"Fluorinated indole-imidazole conjugates: selective orally bioavailable 5-HT7 receptor low-basicity agonists, potential neuropathic painkillers","volume":"170","author":"Hogendorf","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1021\/acs.jmedchem.6b01367","article-title":"Combining molecular scaffolds from FDA approved drugs: application to drug discovery","volume":"60","author":"Taylor","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejmech.2014.03.066","article-title":"Synthesis, radiolabeling and in\u00a0vivo evaluation of [11C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT7 receptor","volume":"79","author":"Hansen","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib25","series-title":"Smith and Williams\u2019 Introduction to the Principles of Drug Design and Action","first-page":"387","article-title":"Neurotransmitters, agonists and antagonists","author":"Sewell","year":"1998"},{"key":"10.1016\/j.ejmech.2020.112395_bib26","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1021\/jm070487n","article-title":"Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2","volume":"50","author":"Leopoldo","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib27","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1021\/jm800615e","article-title":"Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III","volume":"51","author":"Leopoldo","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00221-013-3498-0","article-title":"Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters","volume":"230","author":"Lacivita","year":"2013","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejmech.2020.112395_bib29","first-page":"8e14","article-title":"High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study","volume":"821","author":"Shimokawa","year":"2005","journal-title":"J.\u00a0Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ejmech.2020.112395_bib30a","doi-asserted-by":"crossref","first-page":"56657","DOI":"10.1021\/jm200547z","article-title":"Optimization of (arylpiperazinylbutyl)oxindoles exhibiting selective 5- HT7 receptor antagonist activity","volume":"54","author":"Volk","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib30b","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ejmech.2014.08.023","article-title":"Structure-activity relationships and molecular modeling studies of novel arylpiperazinylalkyl 2-benzoxazolones and 2-benzothiazolones as 5-HT7 and 5-HT1A receptor ligands","volume":"85","author":"Salerno","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib30c","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejmech.2016.02.024","article-title":"Rational design in search for 5-phenylhydantoin selective 5-HT7R antagonists. Molecular modeling, synthesis and biological evaluation","volume":"112","author":"Kucwaj-Brysz","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib31","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib32","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1021\/jm070721+","article-title":"4-[omega-[4-arylpiperazin-1-yl]alkoxy]phenyl)imidazo[1,2-a]pyridine derivatives: fluorescent high-affinity dopamine D3 receptor ligands as potential probes for receptor visualization","volume":"50","author":"Leopoldo","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib33","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1021\/jm400408r","article-title":"Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics","volume":"56","author":"Chen","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13318-018-0472-z","article-title":"A\u00a0population pharmacokinetic and pharmacodynamic analysis of RP5063 Phase 2 study data in patients with schizophrenia or schizoaffective disorder","volume":"43","author":"Cantillon","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2020.112395_bib35","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/jm8014553","article-title":"Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7\/5-HT1A receptor selectivity","volume":"52","author":"Medina","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in\u00a0vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112395_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejmech.2016.05.005","article-title":"Structural modifications of the serotonin 5-HT7 receptor agonist N-(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve in\u00a0vitro microsomal stability: a case study","volume":"120","author":"Lacivita","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1517\/17425250903405622","article-title":"Use of intrinsic clearance for prediction of human hepatic clearance","volume":"6","author":"Chao","year":"2010","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2020.112395_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/adt.2007.103","article-title":"An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion","volume":"6","author":"McNaney","year":"2008","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejmech.2020.112395_bib40","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejmech.2012.06.043","article-title":"Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design","volume":"57","author":"Di","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib41","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3109\/00498254.2011.603388","article-title":"Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats","volume":"41","author":"Lee","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2020.112395_bib42","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Swainston Harrison","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112395_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0278-6915(01)00118-1","article-title":"Methods of in\u00a0vitro toxicology","volume":"40","author":"Eisenbrand","year":"2002","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejmech.2020.112395_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.toxlet.2006.04.002","article-title":"The combined use of human neural and liver cell lines and mouse hepatocytes improves the predictability of the neurotoxicity of selected drugs","volume":"165","author":"Mannerstr\u00f6m","year":"2006","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejmech.2020.112395_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199348","article-title":"Construction of an integrated database for hERG blocking small molecules","volume":"13","author":"Sato","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.112395_bib46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in\u00a0vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Jr Crumb","year":"2016","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejmech.2020.112395_bib47","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuropharm.2016.10.013","article-title":"Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in\u00a0vivo antimyotonic activity","volume":"113","author":"De Bellis","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.112395_bib48","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hipo.20940","article-title":"5-HT1A and 5-HT7 receptors differently modulate AMPA receptor-mediated hippocampal synaptic transmission","volume":"22","author":"Costa","year":"2012","journal-title":"Hippocampus"},{"key":"10.1016\/j.ejmech.2020.112395_bib49","first-page":"1169","article-title":"Primary care for adults on the autism spectrum","volume":"98","author":"Nicolaidis","year":"2014","journal-title":"Med. Clin."},{"key":"10.1016\/j.ejmech.2020.112395_bib50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF01537990","article-title":"Maintenance of sameness in children with Kanner\u2019s syndrome","volume":"3","author":"Prior","year":"1973","journal-title":"J.\u00a0Autism Child. Schizophr."},{"key":"10.1016\/j.ejmech.2020.112395_bib51","first-page":"457","article-title":"Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods Find","volume":"29","author":"Silvestre","year":"2007","journal-title":"Exp. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112395_bib52","unstructured":"J W Brown, A R Gangloff, A J Jennings, P H Vu, Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, (2010) WO2010\/111626."},{"key":"10.1016\/j.ejmech.2020.112395_bib53","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jlcr.965","article-title":"Synthesis of an 18F-labelled high affinity \u03b21-adrenoceptor PET radioligand based on ICI 89,406","volume":"48","author":"Wagner","year":"2005","journal-title":"J.\u00a0Label. Compd. Radiopharm."},{"key":"10.1016\/j.ejmech.2020.112395_bib54","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.bmc.2013.02.038","article-title":"Discovery of aryl-biphenyl-2-ylmethylpiperazines as novel scaffolds for 5-HT7 ligands and role of the aromatic substituents in binding to the target receptor","volume":"21","author":"Kim","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0040-4020(01)90506-X","article-title":"Oxidation of putrescine and cadaverine derivatives by diamine oxidases","volume":"47","author":"Equi","year":"1991","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2020.112395_bib56","doi-asserted-by":"crossref","first-page":"7695","DOI":"10.1016\/0040-4039(96)01759-5","article-title":"Asymmetric synthesis of the C(10)-C(16) segment of the bryostatins","volume":"37","author":"Lampe","year":"1996","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2020.112395_bib57","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/07328319808003482","article-title":"Potential antiviral agents. Part II. Synthesis and antiviral evaluation of pyrazinones substituted with acyclic chains","volume":"17","author":"Davis","year":"1998","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.ejmech.2020.112395_bib58","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.bmc.2014.01.016","article-title":"Design, synthesis, radiolabeling and in\u00a0vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT7 receptor","volume":"22","author":"Lacivita","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112395_bib59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pain.2009.01.010","article-title":"Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine","volume":"142","author":"Desaphy","year":"2009","journal-title":"Pain"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420303652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420303652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:12:04Z","timestamp":1759327924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420303652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":61,"alternative-id":["S0223523420303652"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112395","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Privileged scaffold-based design to identify a novel drug-like 5-HT7 receptor-preferring agonist to target Fragile X syndrome","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112395"}}